Dynavax Technologies | DVAX - Operating Profit



Dynavax Technologies reported $10.86M in Operating Profit for its fiscal quarter ending in June of 2025.


Operating Profit Change Date
AbbVie USD 5.72B 1.98B Jun/2025
Adma Biologics USD 42.8M 5.72M Jun/2025
Amgen USD 2.66B 1.37B Jun/2025
AstraZeneca USD 3.51B 166M Jun/2025
Biogen USD 851.8M 540.6M Jun/2025
BioMarin Pharmaceutical USD 276.89M 52.99M Jun/2025
Bristol-Myers Squibb USD 3.77B 366M Jun/2025
Dynavax Technologies USD 10.86M 34.49M Jun/2025
Gilead Sciences USD 2.7B 467M Jun/2025
Glaxosmithkline GBP 2.44B 1.74B Jun/2025
Merck USD 6.36B 494M Jun/2025
Neurocrine Biosciences USD 145.6M 121.9M Jun/2025
Novartis USD 4.86B 201M Jun/2025
Pfizer USD 2.6B 1.06B Jun/2025
Regeneron Pharmaceuticals USD 1.08B 487.8M Jun/2025
Roche Holding CHF 4.39B 1.04B Dec/2024
Sarepta Therapeutics USD 115.58M 415.96M Jun/2025
TG Therapeutics USD 34.84M 26.22M Jun/2025
Vertex Pharmaceuticals USD 1.15B 123.1M Jun/2025